Adipotide

Origin and Discovery

Adipotide — also called FTPP (fat-targeted proapoptotic peptide) or "prohibitin-targeting peptide" — is a chimeric synthetic peptide designed at MD Anderson Cancer Center by Wadih Arap and Renata Pasqualini, first published in the mid-2000s. It was born from the Arap–Pasqualini group's long-running program of in vivo phage display, a technique that identifies peptide ligands homing to specific vascular beds by injecting random peptide libraries into animals and recovering phage from target tissues. That approach had previously identified peptides homing to tumor vasculature; adipotide applied the same logic to the vasculature of white adipose tissue.

The molecule has two functional halves joined by a linker: a nine-amino-acid homing sequence (CKGGRAKDC) that binds prohibitin on the surface of white adipose endothelial cells, and a pro-apoptotic domain (D(KLAKLAK)₂) that disrupts mitochondrial membranes once internalized, triggering apoptosis.

Mechanism of Action

Adipotide exploits a tissue-specific vascular address. Prohibitin is normally an intracellular mitochondrial protein, but in white adipose endothelium it is also expressed on the luminal surface — one of the few such tissue-selective markers identified. When adipotide is injected systemically, the homing domain binds prohibitin on fat-supporting capillary endothelium; the pro-apoptotic KLAKLAK domain then perforates mitochondrial membranes in those endothelial cells, causing vascular apoptosis. With its blood supply ablated, the overlying white adipose tissue undergoes atrophy and is resorbed. The weight loss is therefore a consequence of targeted adipose-vascular destruction, not appetite suppression or metabolic modulation.

Evidence Base

The preclinical work is striking. In obese rhesus macaques (Barnhart et al., Science Translational Medicine 2011), four weeks of daily subcutaneous adipotide produced approximately 11% body-weight reduction and roughly 38% reduction in adipose mass, accompanied by improved insulin sensitivity. The effect persisted after drug discontinuation. Rodent studies showed comparable adipose-selective effects without apparent damage to other organs at therapeutic doses.

Human clinical data is extremely limited. A Phase 1 trial in obese prostate cancer patients was initiated in the early 2010s at MD Anderson. Published results have been modest and narrow. There is no FDA-registered Phase 2 or 3 efficacy trial, and no approved or late-stage indication as of early 2026. The gap between the macaque data and a commercial drug is, at this point, more than a decade old with limited visible progress.

Safety Considerations

Adipotide's mechanism carries a specific risk profile unlike that of metabolic hormones. Key concerns documented in preclinical and early human work:

• Renal toxicity. The kidney proximal tubule also expresses prohibitin, and dose-limiting nephrotoxicity has been the most-reported adverse finding in primate and early human studies.
• Dehydration and electrolyte disturbance. Related to renal effects.
• Unknown long-term consequences of endothelial ablation. Whether the affected adipose vascular bed regenerates normally over years is not well characterized.

Unlike GLP-1 agonists — which act reversibly on appetite and metabolism — adipotide's effect is a frank destruction of tissue. The reversibility, regenerative response, and implications for cold-induced thermogenesis and metabolic flexibility are not fully established.

Practical Considerations and Gray-Market Use

Adipotide is not an FDA-approved drug. It is not legally prescribable for obesity in any major jurisdiction. A small number of research-chemical suppliers market it, typically lyophilized for subcutaneous injection. This gray-market use is taking place entirely ahead of any meaningful human safety or efficacy data, and adipotide's renal-toxicity signal in well-conducted primate studies is a reason to treat such use as genuinely higher risk than most compounds on this library. Anyone comparing weight-loss strategies should view the established GLP-1 class — semaglutide, tirzepatide — as a categorically better-understood alternative.

The Bottom Line

Adipotide is a scientifically elegant proof-of-concept for vascular-targeted therapeutics. Its macaque data is genuinely impressive. Its human development has stalled, the renal-toxicity profile is real, and the gap between bench and clinic is large. For most readers it is a research curiosity, not a viable weight-loss option.